Acute hepatic cytolysis in an HIV-infected patient taking atazanavir |
|
Applications de séquençage haut-débit pour la recherche en virologie. Résistance de VIH-1 et de VHC aux antiviraux et caractérisation profonde des chaines de transmission de VHC. |
|
Caractérisation du réservoir viral et des anticorps chez des enfants infectés par le VIH en suppression virologique au Mali. |
|
Cascade de prise en charge de l'hépatite C chronique en France métropolitaine |
|
La co-infection VIH - hépatite B chronique : déterminants de la fibrose hépatique et impact des traitements antiviraux |
|
Conséquences de l'infection par le VHB chez les personnes séropositives en Afrique subsaharienne à l'ère du traitement antirétroviral précoce |
|
Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment |
|
Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region |
|
Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients |
|
Efficacité et tolérance de l'association ténofovir-abacavir au sein d'une multithérapie antirétrovirale |
|
Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results |
|
Epidémiologie de la leptospirose aux Antilles françaises : apports du diagnostic par biologie moléculaire dans l'étude des facteurs de risques, des facteurs pronostiques et de l'incidence |
|
Épidémiologie et histoire naturelle de la variole du singe en République Centrafricaine |
|
Epidemiology of leptospirosis in French West Indies : contributions of diagnosis by molecular biology in the study of risk factors, pronostic factors, and incidence. |
|
Estimated average annual rate of change of CD4 |
|
EVALUATION DE L'UTILISATION DES FLUOROQUINOLONES A L'HOPITAL : EXEMPLE DE L'HOPITAL SAINT-ANTOINE |
|
Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort |
|
Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues |
|
femmes sauveront l'hôpital une vie de soignante |
|
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. |
|
HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study |
|
High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients |
|
[HIV infection] |
|
How Sexual network modeling and simulation can help in the understanding of HIV epidemiology. |
|
Impact of a conditional cash transfer and of a lipid-based nutrient supplement on child stunting in rural Mali : analysis of a cluster-randomized controlled trial. |
|
Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial |
|
An improved understanding of severe liver morbidity in HIV-infected individuals |
|
Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin |
|
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. |
|
L'application d'algorithmes de décision et l'utilisation de tests rapides permettent-elles d'optimiser le dépistage et la prévention de l'hépatite B ? |
|
Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH) |
|
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. |
|
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals |
|
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire |
|
Lyme Borreliosis : from exposure to severe clinical manifestations. |
|
médecin une infectiologue au temps du corona |
|
Metabolic disorders and cardiovascular risk in treatment-naive HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle |
|
Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients |
|
Natural history and epidemiology of the monkeypox in Central African Republic. |
|
Non-Alcoholic Fatty Liver Disease in France, Epidemiology and Prognosis : analysis of Data from the Constances Cohort and the National Health Data System (SNDS). |
|
Non-O:1 and non-O:139 Vibrio cholerae septicemia and pyomyositis in an immunodeficient traveler returning from Tunisia |
|
Operational research on emerging infectious diseases in Sub-saharan Africa. |
|
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. |
|
Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France |
|
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications |
|
Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients |
|
Prise en charge de l'hépatite C dans les pays à ressources limitées en santé : quels outils et quelles stratégies diagnostiques ? |
|
Pronostic à long terme des personnes diagnostiquées en primo-infection VIH-1 |
|
La recherche opérationnelle sur les maladies infectieuses à potentiel épidémique et menaçant en Afrique Sub-saharienne |
|
Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients |
|
Réseaux de contacts sexuels et infections par le VIH : apport de leur modélisation et de la simulation dans la compréhension de l'épidémie |
|
Residual mortality of people living with HIV cured of HCV by direct-acting antivirals. |
|
Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy. |
|
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen |
|
Risque résiduel de décès chez les personnes vivant avec le VIH et guéries de l'hépatite C par antiviraux à action directe |
|
Rôle du récepteur adipocytaire des glucocorticoïdes dans l'expansion et la vascularisation du tissu adipeux |
|
Santé publique médecine légale, médecine du travail |
|
Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage |
|
Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir |
|
Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons |
|
Testing recommendations and rapid tests are-they tools to optimize screening and prevention of hepatitis B?. |
|
Traitement du virus de l'hépatite C (VHC) par agents antiviraux directs : modélisation de l'optimisation des traitements et impact sur l'histoire naturelle et l'épidémiologie |
|
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients |
|
Ultra-deep sequencing applications in virology research |
|
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. |
|
Use of drug dispensing data for the identification and quantification of adverse effects associated with the consumption of prescribed drugs in ambulatory settings. |
|
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV. |
|
Utilisation des données de délivrances pharmaceutiques pour l'identification et la quantification des effets indésirables associées à la consommation des médicaments prescrits en milieu extrahospitalier |
|